Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Imaging Studies II: Positron Emission Tomography and Scintigraphy

Imaging Studies II: Positron Emission Tomography and Scintigraphy

Positron Emission Tomography (PET) is a medical imaging technique that provides crucial insights into the body's physiological functions at a molecular level. It is an indispensable resource for diagnosing, staging, and monitoring various illnesses, notably cancer, neurological disorders, and cardiovascular conditions.
Fundamental Principles of PET

Positron Emission Tomography

Positron Emission Tomography

Positron emission tomography (PET) is a medical imaging technique involving radiopharmaceuticals — substances that emit short-lived radiation. Although the first PET scanner was introduced in 1961, it took 15 more years before radiopharmaceuticals were combined with the technique and revolutionized its potential.
One of the main requirements of a PET scan is a positron-emitting radioisotope, which is produced in a cyclotron and then attached to a substance used by the part of the body...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Capmatinib targeted therapy in MET-fusion driven radiation induced glioma.

Frontiers in oncology·2026

Same author

Towards fair decentralized benchmarking of healthcare AI algorithms with the Federated Tumor Segmentation (FeTS) challenge.

Nature communications·2025

Same author

Correction to: Guiding principles on the education and practice of theranostics.

European journal of nuclear medicine and molecular imaging·2025

Same author

National Institutes of Health Funding to Support Radiation Oncology Research: A Comparative Trend Analysis Over a Decade, 2011-2021.

Advances in radiation oncology·2025

Same author

Improved Survival and Prognostication in Melanoma Patients With Brain Metastases: An Update of the Melanoma Graded Prognostic Assessment.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2025

Same author

Racial Disparities in Cancer Guideline-Concordant Treatment Using Surveillance, Epidemiology, and End Results Data for Patients With NSCLC.

JTO clinical and research reports·2025

Search research articles

Related Experiment Video

Updated: Jun 1, 2025

Harnessing the Bioorthogonal Inverse Electron Demand Diels-Alder Cycloaddition for Pretargeted PET Imaging

Harnessing the Bioorthogonal Inverse Electron Demand Diels-Alder Cycloaddition for Pretargeted PET Imaging

Published on: February 3, 2015

The Emerging Potential of Lead-212 Theranostics.

Kristin A Plichta¹, John M Buatti¹

¹Department of Radiation Oncology, University of Iowa Carver College of Medicine, Iowa City, IA, USA.

Hematology/Oncology Clinics of North America

|January 18, 2025

Summary

Alpha-emitting radiopharmaceuticals offer advantages over beta-emitters for personalized theranostics. This article explores the potential of lead-212 as a theranostic agent for improved cancer treatment with reduced toxicity.

Keywords:

Lead-212 Radiopharmaceuticals Targeted alpha therapy Theranostics

More Related Videos

Enhancing Efficiency and Radiolabeling Yields of Carbon-11 Radioligands for Clinical Research Using the Loop Method

Enhancing Efficiency and Radiolabeling Yields of Carbon-11 Radioligands for Clinical Research Using the Loop Method

Published on: December 20, 2024

Development of a 68Gallium-Labeled D-Peptide PET Tracer for Imaging Programmed Death-Ligand 1 Expression

Development of a 68Gallium-Labeled D-Peptide PET Tracer for Imaging Programmed Death-Ligand 1 Expression

Published on: February 3, 2023

Related Experiment Videos

Last Updated: Jun 1, 2025

Harnessing the Bioorthogonal Inverse Electron Demand Diels-Alder Cycloaddition for Pretargeted PET Imaging

Harnessing the Bioorthogonal Inverse Electron Demand Diels-Alder Cycloaddition for Pretargeted PET Imaging

Published on: February 3, 2015

Enhancing Efficiency and Radiolabeling Yields of Carbon-11 Radioligands for Clinical Research Using the Loop Method

Enhancing Efficiency and Radiolabeling Yields of Carbon-11 Radioligands for Clinical Research Using the Loop Method

Published on: December 20, 2024

Development of a 68Gallium-Labeled D-Peptide PET Tracer for Imaging Programmed Death-Ligand 1 Expression

Development of a 68Gallium-Labeled D-Peptide PET Tracer for Imaging Programmed Death-Ligand 1 Expression

Published on: February 3, 2023

Area of Science:

Nuclear medicine and oncology

Background:

Theranostics combines diagnostic and therapeutic nuclear medicine for personalized treatment.
Current theranostics primarily utilize beta-emitting radiopharmaceuticals.
Alpha-emitting radiopharmaceuticals present potential advantages due to their physical characteristics.

Purpose of the Study:

To review the potential of alpha-emitters in theranostics.
To focus on lead-212 (212Pb) as a theranostic agent.

Main Methods:

Review of existing literature on alpha-emitters and theranostics.
Analysis of the properties of lead-212 for therapeutic applications.

Main Results:

Alpha-emitters offer greater cell-killing potential compared to beta-emitters.
Alpha-emitters have a shorter range, potentially reducing toxicity to surrounding healthy tissues.
Lead-212 possesses suitable decay properties for theranostic applications.

Conclusions:

Lead-212 shows significant promise as a theranostic agent.
Further research and clinical trials are warranted to explore the full potential of 212Pb-based theranostics.